We have detected that you are using an Ad Blocker. PracticeUpdate is free to end users but we rely on advertising to fund our site. Please consider supporting PracticeUpdate by whitelisting us in your ad blocker.
We have sent a message to the email address you have provided, . If this email is not correct, please update your settings with your correct address.
The email address you provided during registration, , does not appear to be valid. Please update your settings with a valid address before to continue using PracticeUpdate.
Welcome to PracticeUpdate! We hope you are enjoying access to a selection of our top-read and most recent articles. Please register today for a free account and gain full access to all of our expert-selected content.
You can find your saved items on your dashboard, in the "saved" tab.
You've recommended your first item
Your recommendations help us improve our content suggestions for you and other PracticeUpdate members.
You've subscribed to your first topic alert
What does that mean?
Each day, we'll check to see if new items have been published to the topics you're subscribed to, and we'll send you one email with all of the new items from that day.
We'll keep all topic alert notifications available on your dashboard for 30 days, to make sure you don't miss anything.
Lastly, whenever you have unread items in the topics you've subscribed to, the "Alerts" icon will light up in the main menu. Just click on the bell to see your five most-recent, unread notifications.
This article raises and addresses several concerning indirect effects of the COVID-19 pandemic on routine care of patients with pulmonary diseases. Topics include both benefits and shortcomings of telehealth with suggested strategies to maximize positive impact of virtual encounters, as well as considerations when deciding whether the risk of exposing a vulnerable patient to the healthcare setting is worthwhile to achieve a diagnostic or treatment modality.
This paper suggests strategies to best balance continuing diagnostic and treatment pathways while being cautious of unnecessary healthcare setting exposures for these vulnerable patients.
– Amy Korwin, MD
This abstract is available on the publisher's site.
On a new-normal afternoon of calling patients virtually for follow-up visits, I was jolted by a conversation that typically would have ended with a seamlessly executed plan. I called Ms. M, my 67-year old patient with interstitial lung disease. She promptly answered the phone, having been recently reminded of her virtual appointment by our clinic coordinator. She explained that she was still coughing, and that perhaps her dyspnea had worsened, though it was hard to tell as she was sheltering-in-place. As our conversation went on, I was slowly becoming aware that the challenges of this visit were going to transcend beyond the initial stumble of how to check someone into the virtual waiting room. Exactly how far could she walk before having to stop because of dyspnea? Did her lungs sound different? Had her FEV1 declined? Was her fibrosis progressing? Was a CT scan worth exposing her to the risk of COVID-19 infection? Would I increase immunosuppression even if it was progressing? Each clinic visit now posed these new and unanticipated dilemmas.